Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06370858
Other study ID # GA45392
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date July 24, 2023
Est. completion date November 1, 2025

Study information

Verified date April 2024
Source Hoffmann-La Roche
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This Phase 2, randomized, double-blind, multicenter, induction and maintenance study is designed to evaluate the safety and efficacy of RVT-3101 in adult participants with moderate to severe active Crohn's disease.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 20
Est. completion date November 1, 2025
Est. primary completion date July 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Moderately to severely active CD as defined by Crohn's Disease Activity Index (CDAI) and Simple Endoscopic Score for CD (SES-CD), assessed by central read - Elevated very soft or liquid stool frequency and/or abdominal pain - Must have no response, insufficient response, loss of response and/or intolerance to at least 1 conventional therapy (e.g. corticosteroids) or advanced therapy - Diagnosis of ulcerative colitis, indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis or active diverticular disease Exclusion Criteria: - Short gut syndrome - Presence of an ostomy or ileoanal pouch - Bowel resection or diversion with ~6-months

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
RVT-3101
Induction and maintenance treatment

Locations

Country Name City State
Belgium UZ Gent Gent
Belgium AZ Delta Roeselare
Bulgaria MBAL Hadzi Dimitar Sliven
Bulgaria UMHAT Prof. Dr. Stoyan Kirkovich Stara Zagora
Canada (G.I.R.I.) GI Research Institute Vancouver British Columbia
Canada TDDA Specialty Research Woodbridge Ontario
France CHU de Nantes Nantes cedex 1
France Institut des MICI, Clinique Ambroise Paré Neuilly sur Seine
France CHRU de Nancy Brabois Vandoeuvre Les Nancy
Germany Praxis Westend Studien Berlin
Germany Zentrum für Gastroenterologie Saar MVZ GmbH Saarbrücken
Hungary Clinexpert Kft. Budapest
Hungary Semmelweis Egyetem, II. Belgyógyászati Klinika Budapest
Hungary Semmelweis University Belgyogyaszati es Onkologiai Klinika Budapest
Poland Synexus Polska Sp. z o.o. Oddzial w Czestochowie Cz?stochowa
Poland MZ Badania Slowik Zymla Sp.j. Knurów
Poland Twoja Przychodnia-Szczecinskie Centrum Medyczne Szczecin
Poland WIP Warsaw IBD Point Profesor Kierkus Warszawa
Poland MIGRE Polskie Centrum Leczenia Migreny Wroc?aw
Slovakia ABAWI spol. s r.o. Bratislava
Slovakia Gastro Ambulancia - Endomed Košice
Spain Hospital Universitario de Fuenlabrada Madrid
Spain FISEVI Sevilla
Spain Hospital Universitario y Politecnico la Fe de Valencia Valencia
United States Brigham and Women's Hospital Boston Massachusetts
United States Access Research Institute Brooksville Florida
United States Clinical Research Institute of Michigan Chesterfield Michigan
United States Digestive Health Specialists Dothan Alabama
United States VVCRD Research Garden Grove California
United States Medical Research Center of Connecticut, LLC Hamden Connecticut
United States Baylor College of Medicine. Houston Texas
United States Indiana University Indianapolis Indiana
United States I.H.S Health Northwell Health Kissimmee Florida
United States United Medical Doctors Los Alamitos California
United States NRC Research Institute Orange California
United States Digestive Disease Consultants Orange Park Florida
United States Endoscopic Research, Inc. Orlando Florida
United States Revival Clinical Research Orlando Florida
United States Inland Empire Liver Foundation Rialto California
United States Amicis Research Center Santa Clarita California

Sponsors (1)

Lead Sponsor Collaborator
Hoffmann-La Roche

Countries where clinical trial is conducted

United States,  Belgium,  Bulgaria,  Canada,  France,  Germany,  Hungary,  Poland,  Slovakia,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of participants achieving clinical remission by CDAI Induction of Clinical Remission by CDAI Week 14
Secondary Proportion of participants achieving endoscopic response Induction of Endoscopic Response Week 14
Secondary Proportion of participants achieving clinical response by CDAI Induction of Clinical Response by CDAI Week 14
Secondary Proportion of participants achieving endoscopic remission Induction of Endoscopic Response Week 14
Secondary Proportion of participants achieving clinical remission by CDAI and endoscopic response Induction of Clinical Remission by CDAI and Endoscopic Response Week 14
Secondary Incidence of treatment-emergent adverse events (TEAE), serious adverse events (SAE) and AE leading to discontinuation Safety and Tolerability Week 14
Secondary Proportion of participants achieving clinical response by PRO2 Induction of clinical response by PRO2 Week 14
Secondary Proportion of participants achieving clinical remission by PRO2 Induction of clinical remission by PRO2 Week 14
Secondary Trough Concentration (Ctrough) Up to Week 64
Secondary Percentage of Participants with Anti-drug antibodies (ADA) Up to Week 64
Secondary Percentage of Participants with Neutralizing Antibodies (NAb) Up to Week 64
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04046913 - The ADDapt Diet in Reducing Crohn's Disease Inflammation N/A
Recruiting NCT05169593 - Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy Phase 4
Recruiting NCT06116604 - Early Bowel Resection for Terminal Ileal Crohn's Disease
Recruiting NCT05294107 - Intestinal Organoids N/A
Recruiting NCT05316584 - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy N/A
Recruiting NCT05627128 - A Culturally Tailored Dietary Intervention to Treat Crohn's Disease N/A
Withdrawn NCT04349449 - ENTYVIO in Bio-naive Patients With Moderate/Severe Crohn's Disease (CD) in Daily Practice
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Completed NCT03058679 - Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn's Disease N/A
Completed NCT02871635 - BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity Phase 3
Recruiting NCT04266600 - Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease N/A
Recruiting NCT04539665 - Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease. N/A
Recruiting NCT03913572 - Treatment of Perianal Disease Using Adipose-derived Stem Cells
Completed NCT03606499 - Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
Completed NCT03668249 - A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
Terminated NCT04102111 - A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease Phase 2
Recruiting NCT04997733 - Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal Phase 3
Recruiting NCT05906576 - Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients Phase 4
Not yet recruiting NCT04502303 - 18F-FDG and 68Ga-FAPI PET/CT in Crohn's Disease Phase 2
Not yet recruiting NCT04398836 - Preoperative Nutrition for Crohn's Disease Patients Phase 3